The last word starts right now with Ally Veli. Uh once again in for Lawrence. Hey Ally. Uh Jen, I I often jokingly say that your your work keeps me from doing mine as I prep for the show, but uh your show was something else tonight. U I hope everybody saw it. Uh I will be playing some of your monologue in this show just to to remind people how they need to think about these things because you and I in different roles have have seen too much of this and and and been involved in too many of them. And you're r ...

Next is Yashi Arian and she is an international graduate student pursuing an MS in pharmaceutics at Northeastern University and she is passionate about advancing her technical skills and knowledge in the pharmaceutical industry. She's also the current graduate student ambassador for the pharmaceutics program at Nor Eastern. Please join me in welcoming Yashiarian.just like this. Wow. Okay.I just translate sorry about that. I'm not giving these presentations. Okay.So since the talk is about passion, I'm going ...

Health Secretary Robert F. Kennedy Jr. . just announced he's pulling $500 million in federal funds from mRNA vaccine research and development.HHS has determined that mRNA technology poses more risk and benefits for these respiratory viruses. That's why after extensive review, BARTA has begun the process of terminating these 22 contracts totaling just under $500 million. Scientists and doctors condemned the move, pointing out that Kennedy was wrong to suggest mRNA vaccines don't protect against respiratory i ...

The health department is pulling the plug on a half a billion dollars in funding specifically for mRNA vaccine development. Health Secretary Robert F. Kennedy Jr.. calling the technology behind current COVID and RSV vaccines quote ineffective. mRNA vaccines don't perform well against viruses that infect the upper respiratory tract. mRNA only codes for a small part of the viral proteins, usually a single antigen.one mutation and the vaccine becomes ineffective. Scientists and vaccine experts are now coming o ...

RFK Jr cancels $500m in mRNA vaccine development in the US https://t.co/pF1mwajPvc ...

Core Insights - Moderna's experimental mRNA-based flu vaccine has shown a stronger immune response compared to the currently available vaccine in late-stage trials, paving the way for further development of both the flu vaccine and a combination flu and Covid jab [1][3]. Company Developments - In May, Moderna voluntarily withdrew its application for the combination vaccine targeting Covid-19 and influenza, planning to resubmit it with efficacy data from the phase three trial of its standalone flu vaccine [2]. - The company intends to resubmit the application for the combination vaccine and seek approval for its standalone flu shot later this year, with expectations for regulatory approvals for both products next year [3]. Market Position - Moderna is currently a frontrunner against competitors Pfizer and Novavax in the race to market a combination vaccine, with the potential for significant revenue from the multi-billion-dollar markets of Covid, flu, and respiratory syncytial virus [4][5]. Efficacy Data - The phase three trial involved over 40,000 adults aged 50 and above, showing that Moderna's mRNA-1010 vaccine was 26.6% more effective than the standard competitor vaccine [5]. - The mRNA-1010 vaccine demonstrated strong efficacy against major influenza strains, with a 27.4% higher effectiveness in adults aged 65 and older compared to the standard flu vaccine [6]. Public Health Context - Moderna's CEO highlighted the importance of effective vaccines, especially given that flu-related hospitalizations reached a 15-year high during the 2024 to 2025 season, with over 600,000 hospitalizations reported [7]. Safety and Regulatory Engagement - The safety data for the mRNA-1010 vaccine aligns with previous phase three study results, indicating a consistent safety profile [8]. - Moderna is actively engaging with the FDA to clarify regulatory requirements and believes it has a clear path regarding flu vaccine approval [9].